Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US6047491013
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG00MH7T2M7
TKOMF
Mirum Pharmaceuticals Inc
GICS: Health Care · SECTOR: Financial Services · SUB-SECTOR: Insurance—Property & Casualty · THEMEFOLIO: $HLTH
NAME
Mirum Pharmaceuticals Inc
ISIN
US6047491013
TICKER
TKOMF
MIC
XOTC
REUTERS
TKOMF.PK
BLOOMBERG
TKOMF US
Sa., 11.01.2025       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on January 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 53,900 shares of common stock and 26,950 restricted stock units (“RSUs”) to eight new employees under Mirum’s 2020 Inducement P...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Mo., 06.01.2025       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 15,...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Mi., 11.12.2024       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on December 10, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 48,400 shares of common stock and 24,200 restricted stock units (“RSUs”) to five new employees under Mirum’s 2020 Inducement P...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Do., 14.11.2024       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will present data at the American Association for the Study of Liver Disease’s (AASLD) The Liver Meeting®, taking place November 15-19, 2024, in San Diego, California. Enclosed below are the titles that have been accepted for presentation during the meeting. The abstracts are ava...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Di., 12.11.2024       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the third quarter 2024 and provided a business update. “The Mirum team executed across all aspects of the business in the third quarter with growth across all three commercial medicines highlighted by acceleration of LIVMARLI PFIC sales,” said Chris Peetz, chief exec...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Sa., 09.11.2024       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on November 8, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 56,100 shares of common stock and 28,050 restricted stock units (“RSUs”) to seven new employees under Mirum’s 2020 Inducement P...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Do., 07.11.2024       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences: Stifel 2024 Healthcare Conference on Tuesday,...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Mo., 04.11.2024       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report third quarter 2024 financial results on November 12, 2024. Mirum will also host a conference call to discuss the third quarter 2024 financial results and recent corporate progress. Conference call details: Tuesday, November 12, 2024 8:30 a.m. ET / 5:30 a.m. PT Dia...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Do., 31.10.2024       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced its participation in the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) annual meeting taking place November 6-9, 2024, in Hollywood, Florida. Data highlighting clinical benefit and real-world evidence for patients with Alagille syndrome (ALGS)...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Fr., 11.10.2024       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that on October 10, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 34,100 shares of common stock and 17,050 restricted stock units (“RSUs”) to four new employees under Mirum’s 2020 Inducement Pl...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Do., 10.10.2024       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to volixibat as a potential treatment for cholestatic pruritus in patients with primary biliary cholangitis (PBC). The regulatory designation is based on the positive interim analysis of the Phase...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Mi., 11.09.2024       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that on September 10, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 19,700 shares of common stock and 9,850 restricted stock units (“RSUs”) to seven new employees under Mirum’s 2020 Inducement...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Mi., 28.08.2024       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences: Morgan Stanley 22nd Annual Global Healthcare...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Sa., 10.08.2024       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on August 9, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 59,000 shares of common stock and 29,500 restricted stock units (“RSUs”) to eight new employees under Mirum’s 2020 Inducement Pla...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink